N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246
Online ISSN 1827-160X
Xu X. 1, Zhang B. 2, Hao L. 2, Gu J. 2, Liu L. 3, Wang X. 4, Wu M. 5, Zhang P. 6, Cheng H. 5
1 Department of Gynaecology and Obstetrics, Xuzhou Traditional Chinese Medicine Hospital, Xuzhou 221009, China;
2 Department of Gynaecology and Obstetrics, The Afﬁliated School of Clinical Medicine, Xuzhou Medical College, Xuzhou, China;
3 Department of Radiotherapy, Xuzhou City Central Hospital, Xuzhou, China;
4 Pathology Department, Xuzhou Traditional Chinese Medicine Hospital, Xuzhou, China;
5 Department of Traditional Chinese Medicine, First Clinical College, Nanjing University of Traditional Chinese Medicine, Nanjing, China;
6 Department of Traditional Chinese Medicine, Xuzhou City Central Hospital, Xuzhou, China
AIM: We determined the clinical benefit of Chinese medicinal intervention (Xunxi No. 1) in cervical cancer (CC) patients with high-risk human papilloma virus (HR-HPV) infection undergoing radiotherapy (RT).
METHODS: Eighty stage Ia-IIb CC patients receving primary RT were randomly-and-equally divided into treatment (RT+Xunxi No. 1 for 20 days) and control (RT alone) groups. Expression of the HR-HPV (HPV16/18) was detected by in-situ hybridization (ISH) before and after treatment. The 5-year disease-free survival and pelvic lymphnode metastasis (> 0.9 cm diameter shown by CT) rates were determined.
RESULTS: We found that the HR-HPV positivity rate decreased (37.5-67.5%) significantly (P<0.05) in treatment group while the reduction in control group (65.0 – 72.5%) was non-significant. The 3-year disease-free survival rate in treatment group was better than control group (33/40 vs. 27/40). Notably, the difference in two groups was statistically significant (P<0.05) regarding the 5-year disease-free survival (65.0% vs. 42.5%) and pelvic lymphnode metastasis rate (7.5% vs. 25.0%). It was therefore concluded that the early-stage RT with Xunxi No.1 lowered the HPV positivity rate in CC.
CONCLUSION: The higher 5-year disease-free survival rate and the lower pelvic lymphnode metastasis rate in treatment group as compared with control group suggest that Xunxi No.1 clinically benefits CC patients.